A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022 *

; 2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Get up to date on emerging data with BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma presented at the 2022 meetings of ASCO, EHA, Pan Pacific Lymphoma, ESMO, and SOHO with on-demand webcasts, expert podcasts, downloadable slides, commentaries, and a “year in review” module.

Share

Program Content

Activities

Global BTKi for CLL/MCL
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: October 21, 2022

Expires: October 20, 2023

View Activity
BTKi Conversations
Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022
Conference Coverage
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: November 22, 2022

Expires: November 21, 2023

View Activity

Activities

2022 BTKi Highlights
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL in 2022
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 10, 2022

Expires: October 09, 2023

View Activity

Activities

BTKi Therapy for CLL and MCL: ASCO 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 06, 2022

Expires: July 05, 2023

View Activity
BTKi Therapy for CLL and MCL: EHA 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 21, 2022

Expires: July 20, 2023

View Activity
BTKi Therapy for CLL, MCL: PPLC 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 30, 2022

Expires: August 29, 2023

View Activity
BTKi Therapy for CLL, MCL: SOHO 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2022

Expires: October 27, 2023

View Activity

Activities

CLL and MCL: ASCO 2022
Our Thoughts on the Implications of New Data in CLL and MCL From ASCO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2022

Expires: June 29, 2023

View Activity
LLC e LCM: ASCO 2022
Nossas reflexões sobre as Implicações dos novos dados em LLC e LCM da ASCO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2022

Expires: July 11, 2023

View Activity
LLC y LCM: ASCO 2022
Reflexiones sobre las novedades sobre LLC y LCM presentadas en ASCO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2022

Expires: July 11, 2023

View Activity
CLL und MCL: ASCO 2022
Unsere Überlegungen zu den Auswirkungen der neuen Daten zu CLL und MCL von der Jahrestagung der ASCO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2022

Expires: July 11, 2023

View Activity
LLC e MCL: ASCO 2022
Le nostre considerazioni riguardo alle implicazioni dei nuovi dati su LLC e MCL emersi dallASCO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2022

Expires: July 11, 2023

View Activity
LLC et LCM : ASCO 2022
Nos réflexions sur les implications des nouvelles données concernant la LLC et le LCM après l’ASCO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2022

Expires: July 11, 2023

View Activity
CLL and MCL: EHA 2022
New Data on BTK Inhibitors for CLL and MCL: Experts Discuss EHA 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2022

Expires: July 19, 2023

View Activity
CLL und MCL: EHA 2022
Neue Daten zu BTK-Inhibitoren für CLL und MCL: Expertendiskussion EHA 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2022

Expires: August 14, 2023

View Activity
LLC y LCM: EHA 2022
Nuevos datos sobre inhibidores de QBT para la LLC y el LCM: expertos hablan sobre la EHA 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2022

Expires: August 14, 2023

View Activity
LLC e LCM: EHA 2022
Novos dados sobre os inibidores de BTK para LLC e LCM: especialistas discutem o EHA 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2022

Expires: August 14, 2023

View Activity
LLC et LCM : EHA 2022
Nouvelles données sur les inhibiteurs de BTK pour la LLC et le LCM : Des experts discutent de l’EHA 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2022

Expires: August 14, 2023

View Activity
CLL e MCL: EHA 2022
Nuovi dati sugli inibitori di BTK nella CLL e MCL: gli esperti discutono lEHA 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2022

Expires: August 14, 2023

View Activity
CLL and MCL: 2022 Pan Pacific Lymphoma Conference
Insights on New Data With BTK Inhibitors for CLL and MCL From the 2022 Pan Pacific Lymphoma Conference
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 23, 2022

Expires: August 22, 2023

View Activity
LLC et LCM : Pan Pacific Lymphoma Conference de 2022
Aperçu des nouvelles données sur les inhibiteurs de la BTK pour le traitement de la LLC et du LCM lors de la Pan Pacific Lymphoma Conference de 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 30, 2022

Expires: August 29, 2023

View Activity
CLL und MCL: Pan Pacific Lymphoma Conference 2022
Einblicke in neue Daten zu BTK-Inhibitoren bei CLL und MCL aus der Pan Pacific Lymphoma Conference 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 31, 2022

Expires: August 30, 2023

View Activity
CLL e MCL: Conferenza Pan Pacific Lymphoma 2022
Approfondimenti sui nuovi dati relativi agli inibitori di BTK per la CLL e lMCL emersi dalla Conferenza Pan Pacific Lymphoma del 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 31, 2022

Expires: August 30, 2023

View Activity
FAQ: BTKis for CLL/MCL
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 19, 2022

Expires: October 18, 2023

View Activity
FAQ: BTKis for CLL/MCL
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 01, 2022

Expires: October 31, 2023

View Activity
FAQ: BTKis for CLL/MCL
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 02, 2022

Expires: November 01, 2023

View Activity
FAQ: BTKis for CLL/MCL
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 02, 2022

Expires: November 01, 2023

View Activity
CLL and MCL: SOHO 2022 Annual Meeting
Insights on New Data With BTK Inhibitors for CLL and MCL From the SOHO 2022 Annual Meeting
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: November 16, 2022

Expires: November 15, 2023

View Activity
CLL und MCL: Jahresversammlung der SOHO 2022
Einblicke in neue Daten zu BTK-Inhibitoren bei CLL und MCL der Jahresversammlung der SOHO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 28, 2022

Expires: November 27, 2023

View Activity
CLL e MCL: Conferenza annuale della SOHO 2022
Approfondimenti sui nuovi dati relativi agli inibitori di BTK per il trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) come emersi dalla Conferenza annuale della SOHO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 28, 2022

Expires: November 27, 2023

View Activity
LLC y LCM: Junta Anual de SOHO 2022
Conclusiones sobre los nuevos datos relativos a los inhibidores de la TQB para LLC y LCM de la Junta Anual de SOHO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 28, 2022

Expires: November 27, 2023

View Activity
LLC e LCM: Conferência Pan-Pacífico sobre Linfomas 2022
Insights sobre novos dados com inibidores de BTK para LLC e LCM da edição 2022 da Conferência Pan-Pacífico sobre Linfomas (Pan Pacific Lymphoma Conference)
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022
View Activity
LLC y LCM: Conferencia del Pacífico sobre el Linfoma de 2022
Conclusiones sobre los nuevos datos relativos a los inhibidores de la TQB para LLC y LCM de la Conferencia del Pacífico sobre el Linfoma de 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022
View Activity
LLC et LCM : réunion annuelle de la SOHO 2022
Aperçu des nouvelles données sur les inhibiteurs BTK pour le traitement de la LLC et du LCM à l’occasion de la réunion annuelle de la SOHO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022
View Activity
LLC e LCM: Reunião Anual da SOHO 2022
Insights sobre novos dados com inibidores de BTK para LLC e LCM da Reunião Anual da SOHO 2022
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022
View Activity

Activities

BTKi in R/R CLL and MCL
A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

View Activity
BTKi bei R/R CLL und MCL
Eine globale Perspektive: Neue Daten zur BTK-Inhibitor-Therapie bei rezidivierter/refraktärer CLL und MCL in 2022
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 10, 2023

Expires: January 09, 2024

View Activity
Inhibiteur BTK pour le traitement de la LLC ou du LCM récidivant/réfractaire
Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 13, 2023

Expires: January 12, 2024

View Activity
BTKi em LLC e LCM R/R
Uma perspectiva global sobre os dados emergentes da terapia com inibidor de BTK para LLC e LCM recidivantes/refratários em 2022
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 13, 2023

Expires: January 12, 2024

View Activity
Inhibidores de TQB para LLC y LCM R/R
Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2023

Expires: January 22, 2024

View Activity

Faculty

cover img faculity

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

cover img faculity

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

cover img faculity

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

cover img faculity

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

cover img faculity

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.